Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, states that the fear of adverse events, cost-sharing and patient education are all factors that keep patients from complying with medication regimens.
Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, states that the fear of adverse events, cost-sharing and patient education are all factors that keep patients from complying with medication regimens. Dr. Gleason notes that using a value-based insurance design model to eliminate co-payments would be a big investment with little impact on adherence.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More